Diversion Control Division, US Department of Justice, Drug Enforcement Administration

RESOURCES > Federal Register Notices > Notices - 2001 > Denial of Petition

Notices - 2001


Aceto MD, Scates SM, Lowe JA, & Martin BR (1995). Cannabinoid precipitated
           withdrawal by the selective cannabinoid receptor antagonist, SR 141716A. Eur J Pharmacol 282:R1-R2. 
Aceto MD, Scates SM, Lowe JA, & Martin BR (1996). Dependence on
           9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal. J Pharmacol Exper Therap 278:1290-1295. 
Adams IB & Martin BR (1996). Cannabis: Pharmacology and toxicology in animals and
           humans. Addiction 91:1585-1614. 
Agurell S, Gillespie H, Halldin M, Hollister LE, Johansson E, Lindgren JE, Ohlsson A,
           Szirmai M, & Widman M (1984). A review of recent studies on the pharmacokinetics and metabolism of delta-1-tetrahydrocannabinol, cannabidiol and cannabinol in man. In: Harvey DJ (Ed), Marijuana '84. Proceedings of the Oxford Symposium on Cannabis. IRL Press Ltd:Oxford, England, pp. 49-62. 
Agurell S, Halldin M, Lindgren J E et al. (1986). Pharmacokinetics and metabolism of
           delta-1-tetrahydrocannabinoid and other cannabinoids with emphasis on man. Pharmacol Rev 38:21-43. 
Agurell S, Leander K (1971). Stability, transfer and absorption of cannabinoid constituents
           of Cannabis (Hashish) during smoking. Acta Pharm Succica 8:391-402.
Azorlosa J, Heishman S, Stitzer M (1992). Marijuana smoking: effect of varying
           delta-9-tetrahydrocannabinol content and number of puffs. J Pharmacol Exp Ther 261:114-122.
Baker PB, Gough TA, Taylor BJ (1982). The physical and chemical features of Cannabis
           plants grown in the United Kingdom of Great Britain and Northern Ireland from seeds of known origin. Bull Narc 34:27-36.
Baker PB, Gough TA, Taylor BJ (1983). The physical and chemical features of Cannabis
           plants grown in the United Kingdom of Great Britain and Northern Ireland from seeds of know origin--Part II: second generation studies. Bull Narc 35:51-62.
Balster RL & Prescott WR (1992). 9-tetrahydrocannabinol discrimination in rats as a
           model for cannabis intoxication. Neurosci Biobehav Rev 16:55-62.
Barnett G, Chiang C-WN, Perez-Reyes M, Owens SM (1982). Kinetic study of smoking
           marijuana. J Pharmacokin Biopharm 10:495-505. 
Barrett RL, Wiley JL, Balster RL & Martin BR (1995). Pharmacological specificity of
           9-tetrahydrocannabinol discrimination in rats. Psychopharmacology 118:419-424.
Beal JA, & Martin BM (1995). The clinical management of wasting and malnutrition in
           HIV/AIDS. AIDS Patient Care April: 66-74. 
Becker HS (1967). History, culture and subjective experience: an exploration of the social
           bases of drug-induced experiences. J Health Soc Behav 8:163-176. 
Benowitz NL, & Jones RT (1981). Cardiovascular and metobolic considerations in
           prolonged cannabinoid administration in man. J Clin Pharmacol 21:214S-223S.
Bird KD, Boleyn T, Chesher GB, Jackson DM, Starmer GA, & Teo RKC (1980).
           Intercannabinoid and cannabidiol-ethanol interactions and their effects on human performance. Psychopharmacology 71:181-188. 
Bornheim LM, Kim KY, Li J, Perotti BYT, Benet LZ (1995). Effect of cannabidiol
           pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain. Drug Metab Dispos 23:825-831.
Borgen LA, & Davis WM (1974). CBD interaction with 9-tetrahydrocannabinol. Res
           Commun Chem Pathol Pharmacol 7:663-670. Bouquet RJ (1951). Cannabis. Bull Narc 3:14-30.
Brady JV, Hienz RD, & Ator NA (1990). Stimulus functions of drugs and the assessment 
           of abuse liability. Drug Develop Res 20:231-249. 
Brady KT, & Balster RL (1980) the effects of 9- tetrahydrocannabinol alone and in
           combination with cannabidiol on fixed-interval performance in rhesus monkeys. Psychopharmacology 72:21-26.
Braut-Boucher F, Paris M, Cosson L (1977). Mise en evidence de deux types chimiques
           chez le Cannabis sativa originaire d'Afrique du sud. Phytochemistry 16:1445-1448. 
Braut-Boucher F (1978). Etude ecophysiologique et chimique due cannabis sativa L.
           cultive en Phytotron. Mise en evidence d'un type chimique nouveau chez un Chanvre originaire d'Afrique due Sud. Doctoral thesis. University of Paris XI.
Bray JW, Zarkin GA, Ringwalt C, Qi J (2000). The relationship between marijuana 
           initiation and dropping out of high school. Health Econ 9:9-18.
Braut-Boucher F, & Petiard V (1981). Sur la mise en culture in vitro de tissue de differents
           types chimiques de Cannabis sativa L. C R Acad Sci (Paris) 292:833-838.
Browne RG, & Weissman A (1981). Discriminative stimulus properties of
           9-tetrahydrocannabinol: Mechanistic studies. J Clin Pharmacol 21:227S-234S.
Budney AJ, Novy PL, Hughes JR (1999). Marijuana withdrawal among adults seeking
           treatment for marijuana dependence. Addiction 94:1311-1321.
Caldwell DF, Myers SA, Domino EF, & Merriam PE (1969a). Auditory and visual 
           threshold effects of marihuana in man. Percept Motor Skills 29:755-759.
Caldwell DF, Myers SA, Domino EF, & Merriam PE (1969b). Auditory and visual 
           threshold effects of marihuana in man:Addendum. Percept Motor Skills 29:922.
Cappell H, & Pliner P (1974). Cannabis intoxication: the role of pharmacological and
           psychological variables. In: Miller LL (Ed), Marijuana: Effects on human behavior. Academic Press:New York, pp. 233-264.
Carlezon WAJ, Wise RA (1996). Rewarding actions of phencyclidine and related drugs in
           nucleus accumbens shell and frontal cortex. J Neurosci 16:3112-3122.
Carlini EA, & Cunha JA (1981). Hypnotic and antiepileptic effects of cannabidiol. J Clin
           Pharmacol 32:417-427. 
Carlini EA, Karniol IG, Renault PF, Schuster CR (1974). Effects of marijuana in laboratory
           animals and in man. Br J Pharmacol 50:299- 309.
Carlini EA, Leite JR, Tannhauser M, Berardi
           AC (1973). Letter: Cannabidiol and cannabis sativa extract protect mice and rats against convulsive agents. J Pharm Pharmacol 25:664- 665.
[[Page 20072]]

Carney JM, Uwaydah IM, & Balster RL (1977). Evaluation of a suspension system for
           intravenous self-administration studies of water-insoluble compounds in the rhesus monkey. Pharmacol Biochem Behav 7:357-364.
Carriot F, Sasco AJ (2000). Cannabis and cancer. Rev Epidemiol Sante Publique
Chait LD, Burke KA (1994). Preference for "high" versus low- potency marijuana.
           Pharmacol Biochem Behav 49:643-647.
Chait LD, Fischman MW & Schuster CR (1985). "Hangover" effects the morning after
           marijuana smoking. Drug Alcohol Depend 15:229-238. 
Chait LD, & Zacny JP (1992). Reinforcing and subjective effects of oral D9-THC and
           smoked marijuana in humans. Psychopharmacology 107:255-262.
Chait LD, & Pierri J (1992). Effects of smoked marijuana on human performance. In:
           Murphy L, & Bartke A (Eds). Marijuana/Cannabinoids. Neurobiology and Neurophysiology. CRC Press, Boca Raton, FL; pp. 387-423.
Chait LD, Evans SM, Grant KA, Kamien JB, Johanson CE, & Schuster CR (1988).
           Discriminative stimulus and subjective effects of smoked marijuana in humans. Psychopharmacology 94:206-212.
Chen J, Paredes W, Li J, Smith D, Lowinson J, & Gardner EI (1994).
           Psychopharmacology 102:156-162. Chesher GB, & Jackson DM (1974). Anticonvulsant effets of cannabinoids in mice: drug interactions within cannabinoids and cannabinoid interactions with phenytoin. Psychopharmacologia (Berl) 37:255-264.
Chieng B, Williams JT (1998). Increase opioid inhibition of GABA release in nucleus
           accumbens during morphine withdrawal. J Neurosci 18:7033-7039.
Clark LD, & Nakashima EC (1968). Experimental studies with marihuana. Am J Psychiat
Cocchetto DM, Owens SM, Perez-Reyes M, DiGuiseppi S, Miller LL (1981). Relationship
           between delta-9-tetrahydrocannabinol concentration and pharmacologic effects in man. Psychopharmacology (Berl) 75:158-164. 
Coffey C, Lynskey M, Wolfe R, Patton GC (2000). Initiation and progression of cannabis
           use in a population-based Australian adolescent longitudinal study. Addiction 95:1679-1690.
Community Epidemiology Work Group. (1995). Epidemiological trends in Drug Abuse,
           December 1994: Volume 1: Highlights and Executive Summary. National Institute on Drug Abuse, NIH Publication No. 95- 3988, pp. 54-56. 
Compton DR, Rice KC, DeCosta BR, Razdan RK, Melvin LS, Johnson MR, & Martin BR
           (1993). Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J Pharmacol Exper Ther 265:218-226.
Cone EJ, Johnson RE, Paul BD, Mell LD, & Mitchell J (1988). Marijuana-laced brownies:
           Behavioral effects, physiological effects and urinalysis in humans following ingestion. J Anal Toxicol 12:169- 175.
Consroe P, Martin P, & Eisenstein D (1977). Anticonvulsant drug antagonism of
           9-tetrahydrocannabinol seizures in rabbits. Res Commun Chem Pathol Pharmacol 16:1-13. 
Consroe P, Martin P, & Singh V (1981). Antiepileptic potential of cannabidiol analogues.
           J Clin Pharmacol 21:428S-436S. 
Cousens K, DiMascio A (1973). (-)9 THC as an hypnotic: An experimental study of three
           dose levels. Psychopharmacologia (Berl.) 33:355-364.
Crancer JM, Dille JM, Delay JC, Wallace JE, Haykin MD (1969). Comparisons of the
           effects of marihuana and alcohol on simulated driving performance. Science 164:851-854
Crowley TJ, Macdonald MJ, Whitmore EA, Mikulich SK (1998). Cannabis dependence,
           withdrawal, and reinforcing effects among adolescents with conduct symptoms and substance use disorders. Drug Alcohol Depend 50:27-37.
Dalton WS, Martz R, Kenberger L, Rodda BE, & Forney RB (1976). Influence of
           cannabidiol on delta-9-tetrahydrocannabinol effects. Clin Pharmacol Therap 19:300-309.
Darley CF, Tinklenbreg WT, Roth WT, Hollister LE, & Atkinson RC (1973a). Influence of
           marihuana on storage and retrieval processes in memory. Mem Cognit 1:196-200. 
Darley CF, Tinklenbreg WT, Hollister LE, & Atkinson RC (1973b). Marihuana and retrieval
           from short term memory. Psychopharmacologia (Berl.) 29:231-233. deMeijer EPM (1993). Hemp variations as pulp source researched in the Netherlands. Government-funded hemp (Cannabis sativa L.) investigation evaluates stem quality, yield, comparison to woodfibers. Pulp & Paper 67:41-43.
deMeijer EPM, van der Kamp HJ, & van Eeuwijk VA (1992). Characterisation of cannabis
           accessions with regard to cannabinoid content in relation to other plant characters. Euphytica 62:187-200. 
Deneau GA, & Kaymakcalan S. (1971). Physiological and psychological dependence to
           9-tetrahydrocannabinol (THC) in rhesus monkeys. Pharmacologist 13:246.
Devine ML, Dow GJ, Greenberg BR, Holsten DW, Icaza L, Jue PY, Meyers FH, O'Brien E,
           Roberts CM, Rocchio GL, Stanton W, & Wesson DL (1987). Adverse reactions to 9- tetrahydrocannabinol given as an antiemetic in a multicenter study. Clin Pharmacol 6:319-322.
Dewey WL (1986). Cannabinoid pharmacology. Pharmacol Rev 38: 151- 178.
deWit H, & Griffiths RR (1991). Testing the abuse liability of anxiolytic and hypnotic drugs
           in humans. Drug Alcohol Depend 28:83- 111.
deWit H, Bodker B, Ambre J (1992). Rate of increase of plasma drug level influences
           subjective response in humans. Psychopharmacology 107:352-358.
DiMarzo V, Melis M, Gessa GL (1998). Endocannabinoids: endogenous cannabinoid
           receptor ligands with neuromodulatory actions. TINS 21:521-528.
Domino LE, Domino SE, Domino EF (1984). Relation of plasma delta-9- THC
           concentrations to subjective "high" in marijuana users: A review and reanalysis. In: S Agurell, WL Dewey, Willette RE (Eds) The Cannabinoids: chemical, pharmacologic, and therapeutic aspects. Orlando, FL: Academic Press, pp 245-261.
Domino EF, Rennick P, & Pearl JH (1976). Short-term neuropsychopharmacological
           effects of marihuana smoking in experienced male users. In: Braude MC & Szara S (Eds) The Pharmacology of Marihuana. Raven Press: New York, pp 393-412. Doorenbos NJ, Fetterman PS, Quimby MW, Turner CE (1971). Cultivation extraction and analysis of Cannabis sativa L.. Ann NY Acad Sci 191:3-15. 
Doyle E, & Spence AA (1995). Cannabis as a medicine. Br J Anaesth 74:359-361. 
Drew G, & Miller L (1974). Cannabis: Neural mechanisms and behavior--a theoretical
           review. Pharmacol Rev 38:151-178. 
Duffy A, & Milin R (1996). Withdrawal syndrome in adolescent chronic cannabis users. J
           Am Acad Child Adolesc Psychiatry 35:1618-1621.
Ehrenreich H, Rinn T, Kunert HJ, Moeller MR, Poser W, Schilling L, Gigerenzer G, Hoehe
           MR (1999). Specific attentional dysfunction in adults following early start of cannabis use. Pyschopharmacology (Berl) 142:295-301.
Fairbairn JW, Hindmarch I, Simic S, Tylden E (1974). Cannabinoid content of some
           English reefers. Nature 249: 276-278. 
Fairbairn JW, & Liebmann JA (1974). The cannabinoid content of cannabis sativa L.
           grown in England. J Pharmac Pharmacol 26:413- 419.
Fairbairn JW, Liebmann JA, & Simic S (1971). The tetrahydrocannabinol content of
           cannabis leaf. J Pharmac Pharmacol 23:558-559.
Farre M, & Cami J (1991) Pharmacokinetics and abuse liability. Br J Addict
Farrell M, Howes S, Taylor C, Lewis G, Jenkins R, Bebbington P, Jarvis M, Brugha T, Gill
           B, Meltzer H (1998). Substance misuse and psychiatric comorbidity: an overview of the OPCS national psychiatric morbidity survey. Addictive Behaviors 23:909-918.
Farrelly MC, Bray JW, Zarkin GA, Wendling BW (2001). The joint demand for cigarettes
           and marijuana: evidence from the National Household Surveys on Drug Abuse. J Health Econ 20:51-68.
Fernandes M, Schabarak A, Coper H, & Hill R (1974). Modificarion of the 9-THC-actions
           by cannabinol and cannabidiol in the rats. Psychopharmacologia (Berl.) 38:329-338.
Fetterman PS, Doorenbos NJ, Keith ES, Quimby MW (1971). A simple gas liquid
           chromatography procedure for determination of cannabinoidic acids in
           Cannabis sativa L. Experientia 27:988-989. 
[[Page 20073]]

Fetterman PS, Keith ES, Waller CW, Guerrero O, Doorenbos NJ, Quimby MW (1970).
           Mississippi grown Cannabis sativa L.. A preliminary observation on the chemical definition of phenotype and variations in the content versus age, sex, and plant park. J Pharm Sci 60:1246- 1249.
Ferguson DM, Horwood LJ (2000). Does cannabis use encourage other forms of illicit
           drug use? Addiction 95:505-520. 
Foltin RW, Fischman MW, Brady JV, Bernstein DJ, Capriotti RM, Nellis MJ, Kelly TH
           (1990). Motivational effects of smoked marijuana: behavioral contingencies and low-probability activities. J Exp Anal Behav 53:5-19.
Ford RD, Balster RL, Dewey WL, Beckner JS (1977). Delta-9-THC and
           11-OH-delta-9-THC: behavioral effects and relationship to plasma and brain levels. Life Sci 20:1993-2003. 
Gardner EL (1992). Cannabinoid interactions with brain reward systems--The
           Neurobiological basis of cannabinoid abuse. In: Murphy L, & Bartke A (Eds), Marijuana/Cannabinoids: Neurobiology and Neurophysiology. CRC Press, Boca Raton, FL; pp. 275-335. 
Gardner EL, & Lowinson JH (1991). Marijuana's interaction with brain reward systems:
           Update 1991. Pharmacol Biochem Behav 40:571-580. 
Gardner EL, Paredes W, Smith D, Donner A, Milling C, Cohen D, & Morrison D (1988).
           Facilitation of brain stimulation reward by delta-9-tetrahydrocannabinol. Psychopharmacology 96:142-144. 
Gardner EL, Vorel SR (1998). Cannabinoid transmission and reward- related events.
            Neurobiol Dis 5:502-533.
Gauvin DV & Baird TJ (1999). The discriminative stimulus properties of compound drug
           stimuli: a focus on attention. Pharmacology, Biochemistry and Behavior.
Gauvin DV, Cheng EY & Holloway FA (1993). Biobehavioral correlates of alcohol
           hangover. In: Galanter, M. (Ed.) Recent Developments in Alcoholism: Ten Years of Progress NY: Plenum Press, pp. 281-304. 
Gauvin DV, Harland RD, & Holloway FA (1989). Drug discrimination procedures: A
           method to analyze adaptation level of affective states. Drug Develop Res 16:183-194.
Gledhill-Hoyt J, Lee H, Strote J, Wechsler H (2000). Increased use of marijuana and other
           illicit drugs at US colleges in the 1990s: results of three national surveys. Addiction 95:1655-1667. 
Golub A, Johnson BD (1994). The shifting importance of alcohol and marijuana as
           gateway substances among serious drug abusers. Journal on the Studies of Alcohol 55:607-614. 
Goudie AJ (1987). Aversive stimulus properties of drugs: The conditioned taste
           aversion paradigm. In: Greenshaw AJ & Dourish CT (Eds) Experimental Psychopharmacology. Humana Press: Clifton, NJ, pp. 341-391.
Guimares FS, Chiarett TM, Graeff FG, & Zuardi AW (1990). Antianxiety effect of
           cannabidiol in the elevated plus-maze. Psychopharmacology 100:558-559.
Guimares FS, DeAguiar JC, Mechoulam R, Breuer A (1994). Anxiolytic effect of
           cannabidiol derivatives in the elevated plus-maze. Gen Pharmac 25:161-164. 
Gust SW, & Walsh JM (1989). Drugs in the Workplace: Research and Evaluation Data.
           NIDA Monograph No. 91. US Government Printing Office: Washington, DC. 
Hamilton HC (1912). The pharmacopoeia requirements for Cannabis sativa. J Am Pharm
           Assoc 1:200-203. 
Hamilton HC (1915). Cannabis sativa: Is the medicinal value found only in the Indian 
           grown drug. J Am Pharm Assoc 4:448-451. 
Hanus L, Subova D (1989). The amount of main cannabinoid substances in hemp,
           cultivated for industrial fibre production and their changes in the course of one vegetation period. Acta Univ Palacki Olomuc, Fac Med 122:11-23.
Hanus L, Yoshida T, Kreji (1975). Production of 9- tetrahydrocannabinol from hemp
           cultivated in climatic conditions of Czechoslovakia. Acta Univ Palacki Olomuc, Fac Med 74:173-180.
Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW (1999a). Abstinence 
           symptoms following oral THC administration to humans. Psychopharmacology 141:385-394.
Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW (1999b). Abstinence 
           symptoms following smoked marijuana in humans. Psychopharmacology 141:395-404.
Harris RT, Waters W, & McLendon D (1974). Evaluation of the reinforcing capability of
           9-tetrahydrocannabinol in rhesus monkeys. Psychopharmacologia 37:23. 
Harris D, Jones RT, Shank R, Nath R, Fernandez E, Goldstein K, Mendelson J (2000).
           Self-reported marijuana effects and characteristics of 100 San Francisco medical marijuana club members. J Addict Dis 19:89-103.
Heishman SJ, Huestis MA, Henningfield JE, Cone EJ (1990). Acute and residual effects 
           of marijuana: profiles of plasma THC levels, physiological, subjective, and performance measures. Pharmacology Biochemistry & Behavior 37:561-565.
Henningfield JE (1984). Behavioral pharmacology of cigarette smoking. In: Thompson T,
           Dews PB & Barrett JE (Eds), Advances in Behavioral Pharmacology, Volume 4, Academic Press: Orlando, FL, pp 131-210.
Hiltunen AJ, & Jarbe TUC (1986). Interactions between 9- tetrahydrocannabinol and
           cannabidiol as evaluated by drug discrimination procedures in pigeons. Neuropharmacol 25:133-142.
Hiltunen AJ, Jarbe TUC, & Wangdahl K (1988). Cannabinol and cannabidiol in
           combination: temperature, open-field activity, and vocalization. Pharmacol Biochem Behav 30:675-682. 
Hines B, Torrelio M, & Gershon S (1975a). Interactions between cannabinol and
           cannabidiol during abstinence in morphine-dependent rats. Res Comm Chem Pathol Pharmacol 12:185-188. 
Hine B, Torrelio M, & Gershon S. (1975b). Differential effects of cannabidiol and 9-THC
           during abstinence in morphine- dependent rats. Life Sci 17:185-188.
Ho BT, Estevez VS, Englert LF (1973). The uptake and metabolic fate of cannabinoids in
           rat brains. J Pharm Pharmacol 25:488-490.
Hoffman AF, Lupica CR (2001). Direct actions of cannabinoids on synaptic transmission
           in the Nucleus Accumbens: A comparison with opioids. J Physiol 85:72-83.
Hollister LE (1974). Structure activity relationship in man of cannabis constituents and
           homologs and metabolites of 9-tetrahydrocannabinol. Pharmacology 11:3-11.
Hollister LE (1988). Cannabis--1988.(Literature Review). Acta Psychiatr Scand
Hollister LE (1986). Health aspects of cannabis. Pharmacol Rev 38:1-20.
Hollister LE, & Gellespie BA (1975). Interactions in man of delta-9-tetrahydrocannabinol. 
           II. Cannabinol and cannabidiol. Clin Pharmacol Therap 18:80-83.
Howlett AC (1987). Cannabinoid inhibition of adenylate cyclase: relative activities of
           marihuana constituents and metabolites. Neuropharmacology 26:507-512.
Howlett AC, Evans DM, & Houston DB (1992). The cannabinoid receptor. In: Murphy L &
           Bartke A (Eds) Marijuana/Cannabinoids: Neurobiology and Neurophysiology. Boca Raton: CRC Press, pp 38-72. 
Huffman JW, Dai D, Martin BR, & Compton DR (1994). Design, synthesis and
           pharmacology of cannabimimetic indoles. BioMed Chem Lett 4:563- 566

Previous Page | Next Page

NOTICE: This is an unofficial version. An official version of this publication may be obtained directly from the Government Publishing Office (GPO).

Emergency Disaster Relief
National Prescription Drug Take Back Day. Turn in your unused or expired medication for safe disposal here.
RX Abuse Online

Diversion Control Division  •  8701 Morrissette Drive  •  Springfield, VA 22152  •  1-800-882-9539

DOJ Legal Policies and Disclaimers    |    DOJ Privacy Policy    |    FOIA    |    Section 508 Accessibility